Craft

Apellis Pharmaceuticals

Stock Price

$27.4

2024-10-29

Market Capitalization

$3.3 B

2024-10-29

Revenue

$396.6 M

FY, 2023

Apellis Pharmaceuticals Summary

Company Summary

Overview
Apellis Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic compounds. It offers SYFOVRE and EMPAVELI for the treatment of eye and rare diseases through the inhibition of the complement system at the level of C3, the central protein in the complement cascade. The company caters to ophthalmology, rare disease, and research areas.
Type
Public
Status
Active
Founded
2009
HQ
Waltham, MA, US | view all locations
Website
https://apellis.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Cedric Francois

    Cedric Francois, Co-Founder & Chief Executive Officer/President, and Director

  • Pascal Deschatelets

    Pascal Deschatelets, Co-Founder & Chief Scientific Officer

  • Jeffrey Eisele

    Jeffrey Eisele, Chief Development Officer

  • Karen Lewis

    Karen Lewis, Chief People Officer

Operating MetricsView all

Clinical Programs

6
14.3%

FY, 2021

Facility Space, sq. ft.

105.3K

FY, 2021

LocationsView all

6 locations detected

  • Waltham, MA HQ

    United States

    100 5th Avenue

  • San Francisco, CA

    United States

    720 Market Street, 5th Floor

  • Watertown, MA

    United States

    65 Grove Street, Suite 302

  • Kew East, VIC

    Australia

    Level 1, 718 High Street

  • München, BY

    Germany

    Bavaria Towers, Sky Tower, 16. OG, Einsteinstraße 174

  • Zug, ZG

    Switzerland

    Zählerweg 10

Apellis Pharmaceuticals Financials

Summary Financials

Revenue (Q3, 2024)
$196.8M
Net income (Q3, 2024)
($57.4M)
Cash (Q3, 2024)
$396.9M
EBIT (Q3, 2024)
($47.3M)
Enterprise value
$3.3B

Footer menu